CraigNicolasBashMDm.b.a

PubMed

• Relapse May Serve as a Mediator Variable in Longitudinal Outcomes in Multiple Sclerosis.
  Lael Stone, Gary Cutter, Elizabeth Fisher, Nancy Richert, Jennifer McCartin, Joan Ohayon, C. N. Bash, Henry F. McFarland> ;Journal of Neuroimaging. 2016 May 1
• 25 citations
  MRI and clinical activity in MS patients after terminating treatment with interferon beta-1b.
  Nancy D Richert, Mary Christina Zierak, Craig N Bash, Bobbi K. Lewis, Henry F. McFarland, Joseph A. Frank> ;Multiple Sclerosis. 2000 Apr 1
• 30 citations
  Seasonality and pituitary volume
  Paul J. Schwartz, Justin A. Loe, C. N. Bash, Karen E. Bove, Erick H. Turner, Joseph A. Frank, Thomas A. Wehr, Norman E. Rosenthal> ;Psychiatry Research. 1997 Jul 4
• Relationship between inflammatory lesions and cerebral atrophy in multiple sclerosis.
  Richert, N. D., Howard, T., Frank, J. A., Stone, R., Ostuni, J., Ohayon, J., Bash, C., McFarland, H. F.> ;Neurology. 2006 Feb 28
• MRI as a marker for disease heterogeneity in multiple sclerosis.
  Bielekova, B., Kadom, N., Fisher, E., Jeffries, N., Ohayon, J., Richert, N., Howard, T., Bash, C. N., Frank, J. A., Stone, L., Martin, R., Cutter, G., McFarland, H. F.> ;Neurology. 2005 Oct 11
• Optimization of the safety and efficacy of interferon beta 1b and azathioprine combination therapy in multiple sclerosis.
  Pulicken, M., Bash, C. N., Costello, K., Said, A., Cuffari, C., Wilterdink, J. L., Rogg, J. M., Mills, P., Calabresi, P. A.> ;Mult Scler. 2005 Apr
• Interferon-beta-1b slows progression of atrophy in RRMS: Three-year follow-up in NAb- and NAb+ patients.
  Frank, J. A., Richert, N., Bash, C., Stone, L., Calabresi, P. A., Lewis, B., Stone, R., Howard, T., McFarland, H. F.> ;Neurology. 2004 Mar 9
• Methylprednisolone effect on brain volume and enhancing lesions in MS before and during IFNbeta-1b.
  Rao, A. B., Richert, N., Howard, T., Lewis, B. K., Bash, C. N., McFarland, H. F., Frank, J. A.> ;Neurology. 2002 Sep 10
• A pilot study of recombinant insulin-like growth factor-1 in seven multiple sderosis patients.
  Frank, J. A., Richert, N., Lewis, B., Bash, C., Howard, T., Civil, R., Stone, R., Eaton, J., McFarland, H., Leist, T.> ;Mult Scler. 2002 Feb
• Interferon beta-1b and intravenous methylprednisolone promote lesion recovery in multiple sclerosis.
  Richert, N. D., Ostuni, J. L., Bash, C. N., Leist, T. P., McFarland, H. F., Frank, J. A.> ;Mult Scler. 2001 Feb
• Contrast-enhanced magnetic resonance activity in relapsing remitting multiple sclerosis patients: a short term natural history study.
  Bagnato, F., Tancredi, A., Richert, N., Gasperini, C., Bastianello, S., Bash, C., McFarland, H., Pozzilli, C., Frank, J. A.> ;Mult Scler. 2000 Feb
• Serial whole-brain magnetization transfer imaging in patients with relapsing-remitting multiple sclerosis at baseline and during treatment with interferon beta-1b.
  Richert, N. D., Ostuni, J. L., Bash, C. N., Duyn, J. H., McFarland, H. F., Frank, J. A.> ;AJNR Am J Neuroradiol. 1998 Oct
• ELI-spot of Th-1 cytokine secreting PBMC''s in multiple sclerosis: correlation with MRI lesions.
  Calabresi, P. A., Fields, N. S., Farnon, E. C., Frank, J. A., Bash, C. N., Kawanashi, T., Maloni, H., Jacobson, S., McFarland, H. F.> ;J Neuroimmunol. 1998 May 15
• Increased serum levels of soluble CD95 (APO-1/Fas) in relapsing-remitting multiple sclerosis.
  Zipp, F., Weller, M., Calabresi, P. A., Frank, J. A., Bash, C. N., Dichgans, J., McFarland, H. F., Martin, R.> ;Ann Neurol. 1998 Jan
• MRI studies of multiple sclerosis: implications for the natural history of the disease and for monitoring effectiveness of experimental therapies.
  McFarland, H. F., Stone, L. A., Calabresi, P. A., Maloni, H., Bash, C. N., Frank, J. A.> ;Mult Scler. 1996 Nov
• Characterization of MRI response to treatment with interferon beta-1b: contrast-enhancing MRI lesion frequency as a primary outcome measure.
  Stone, L. A., Frank, J. A., Albert, P. S., Bash, C. N., Calabresi, P. A., Maloni, H., McFarland, H. F.> ;Neurology. 1997 Sep
• Increases in soluble VCAM-1 correlate with a decrease in MRI lesions in multiple sclerosis treated with interferon beta-1b.
  Calabresi, P. A., Tranquill, L. R., Dambrosia, J. M., Stone, L. A., Maloni, H., Bash, C. N., Frank, J. A., McFarland, H. F.> ;Ann Neurol. 1997 May
• Interferon beta results in immediate reduction of contrast-enhanced MRI lesions in multiple sclerosis patients followed by weekly MRI.
  Calabresi, P. A., Stone, L. A., Bash, C. N., Frank, J. A., McFarland, H. F.> ;Neurology. 1997 May
• Evaluation of magnetic resonance imaging sensitivity in patients with relapsing remitting multiple sclerosis: baseline versus Betaseron treatment trials.
  Frank, J. A., Bash, C., Stone, L., Petrella, J., Maloni, H., McFarland, H.> ;Acad Radiol. 1996 Aug
• Blood-brain barrier disruption on contrast-enhanced MRI in patients with mild relapsing-remitting multiple sclerosis: relationship to course, gender, and age.
  Stone, L. A., Smith, M. E., Albert, P. S., Bash, C. N., Maloni, H., Frank, J. A., McFarland, H. F.> ;Neurology. 1995 Jun
• The effect of interferon-beta on blood-brain barrier disruptions demonstrated by contrast-enhanced magnetic resonance imaging in relapsing-remitting multiple sclerosis.
  Stone, L. A., Frank, J. A., Albert, P. S., Bash, C., Smith, M. E., Maloni, H., McFarland, H. F.> ;Ann Neurol. 1995 May
• MRI of silicone vitreous ocular implants with phantom correlation.
  Bash, C., Rothman, M., Hamet, M., Sorce, D., Zoarski, G., Mihara, F., Numaguchi, Y.> ;Neuroradiology. 1995 May
• Join now to see all